A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2020

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Nephrotic Syndrome Due to Idiopathic Membranous NephropathySevere Proteinuria Due to Idiopathic Membranous Nephropathy

Interventions

DRUG

100 mg AP1189

100 mg AP1189 tablet

DRUG

Placebo

Matching placebo tablet

Trial Locations (1)

RECRUITING

Aarhus Universitetshospital, Aarhus

All Listed Sponsors

lead

SynAct Pharma Aps

INDUSTRY